BackExact Sciences Overview

Exact Sciences Receivables

Latest receivables for EXAS: $300M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$298.65M
↑ 19.96% YoYΔ $49.69M vs prior year quarter

Peer trimmed avg / median

Loading

Exact Sciences Receivables History

Loading

Exact Sciences vs. peers: Receivables Comparison

Loading

Exact Sciences Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Exact Sciences (EXAS) FAQ

As of the most recent data (December 2025), EXAS shows a receivables of $300M. That compares with $250M in the prior-year period — up 20.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EXAS's receivables is now $300M (was $250M) — a 20.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Exact Sciences is outperforming or lagging.

Tracking EXAS's receivables over time shows whether Exact Sciences is scaling, shrinking, or reshaping that part of the business. The current reading is $300M That compares with $250M in the prior-year period — up 20.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Exact Sciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $300M) with ownership activity and broader fundamentals.

Exact Sciences's receivables is $300M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.